|
Charles Duncan joined JMP Securities in November 2002 as a Managing Director and senior research analyst covering biotechnology.
Prior to joining JMP, Charles had served as Director of U.S. Equities and as a biotechnology analyst at Dresdner Kleinwort Wasserstein Securities since July 2001. Charles previously spent a year at Prudential Vector Healthcare Group and its predecessor, Vector Securities International, as a Senior Vice President following biotechnology and genomics. Charles began his equity research career at Tucker Anthony Cleary Gull, where he covered drug development and therapeutics from March 1997 through May 2000.
Charles is a member of the Association for Investment Management Research, the Denver Society of Security Analysts, the American Association for the Advancement of Science and the Society of Neuroscience.
Charles received a PhD in pharmaceutical sciences from the University of Colorado and a BS in zoology and molecular biology from the University of Wisconsin, Madison. | 